Supporting documents for you
Request cost coverage online with Patient Strength
Helpful materials for your patients
Please enter the number of brochures that you would like to receive in each language, and enter your contact data so that we can send the documents to you.
DISCLAIMER
I agree that my data and usage statistics are stored electronically. The personal data is used to contact you by e-mail. The usage profiles are used for quality assurance and for individual analysis of usage behaviour, as described in the privacy policy. The usage behaviour includes information about when you have opened an e-mail from us or when you have clicked on a certain link in the e-mail. I am aware that I can revoke this consent at any time without justification (e.g. with an AstraZeneca sales representative or via the e-mail received).
Helpful links
TAGRISSO®
Comp: Osimertinib; 40 mg and 80 mg film-coated tablets; List A. Ind: TAGRISSO is indicated as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with non-squamous, non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) exon 19 deletions or exon 21 (L858R) substitution mutations, for the first-line treatment in adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR‑T790M‑mutation who have progressed on or after EGFR TKI therapy, as well as in combination with pemetrexed and platinum‑based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic, non-squamous NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. Dos: 80 mg once daily in monotherapy as well as in combination with pemetrexed and 4 cycles platinum-based chemotherapy. CI: Hypersensitivity to the active substance or to any of the excipients. Concomitant use of St. John’s Wort. W&P: Interstitial lung disease. Erythema multiforme. QTc interval prolongation. LVEF and cardiomyopathy. Diarrhoea. Age and body weight. IA: Strong CYP3A inducers. CYP3A4 substrates and transporters. ADRs: Very common: diarrhoea, stomatitis, rash, dry skin, paronychia, pruritus, platelet count decreased, leukocytes decreased, lymphocytes decreased, neutrophils decreased, blood creatinine increased. Common: interstitial lung disease, epistaxis, palmar-plantar erythrodysaesthesia syndrome, alopecia, urticaria, blood creatine phosphokinase increased, QTc interval prolongation, cardiac failure, left ventricular ejection fraction decreased, erythema multiforme, skin hyperpigmentation. Uncommon, rare, very rare: see www.swissmedicinfo.ch. Date of revision of the text: December 2023.
Further information: www.swissmedicinfo.ch or AstraZeneca AG, Neuhofstrasse 34, 6340 Baar, Switzerland. www.astrazeneca.ch.
Professionals can request the mentioned references from AstraZeneca AG.
You are now leaving the TAGRISSO website of AstraZeneca Switzerland
×You are now leaving the TAGRISSO website of AstraZeneca Switzerland and thus our area of responsibility. The linked pages possess their own terms of use and are possibly subject to other legislation and standards.